Udenafil CAS 268203-93-6

Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC₅₀ of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.

Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.

Loaʻa iā mākou nā hale hana kiʻekiʻe me ka pilina hohonu, hiki iā ia ke hāʻawi iā ʻoe i nā huahana kiʻekiʻe a me nā kumukūʻai hoʻokūkū. A hiki iā mākou ke hāʻawi i nā uku no nā kūʻai nui. A ke hui pū nei mākou me nā ʻoihana lawe ukana ʻoihana he nui, hiki ke hāʻawi i nā huahana me ka palekana a me ka maʻalahi i kou mau lima. ʻO ka manawa hoʻouna ma kahi o 3-20 mau lā ma hope o ka hōʻoia ʻana o ka uku.

Product Name:	Udenafil
Synonyms:	5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;Zydena;Udenafil(DA 8159,Zydena);BenzenesulfonaMide,3-(6,7-dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;Udenafil, DA 8159;CS-1353;Udenafil, >=98%
CAS:	268203-93-6
MF:	C25H36N6O4S
MW:	516.66
EINECS:	251-228-4
Product Categories:	Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	268203-93-6.mol

1. He hale hana ʻoe a he hui kālepa paha?
He compnay mākou e hoʻohui i ka ʻoihana a me ke kālepa, e hāʻawi ana i ka lawelawe hoʻokahi. Hiki ke ʻae ʻia ʻo OEM.

2. Hāʻawi anei ʻoe i nā laʻana? He manuahi a keu paha?
Free samples.The sample's freight fee Pono e uku ma kou aoao.

3. Loaʻa iā ʻoe nā palapala hōʻoia e pili ana i ka mana maikaʻi?
ISO 9001: 2008 palapala hōʻoia e hōʻoia i ka maikaʻi.

4. He aha kaʻu e hāʻawi ai e kiʻi i kahi ʻōlelo?
E haʻi mai ʻo Pls iā mākou i ke ʻano huahana āu e pono ai, ka nui o ke kauoha, ka helu a me nā koi kikoʻī. E hana ʻia ka ʻōlelo no kāu kuhikuhi i ka manawa.

5. He aha ke ʻano o ka uku uku āu e makemake ai? He aha ke ʻano o nā ʻōlelo i ʻae ʻia?
ʻAe ʻia nā ʻōlelo hoʻouna: FOB, CFR, CIF, EXW;
ʻAe ʻia ke kālā uku:USD;
ʻAno uku i ʻae ʻia: T / T, Western Union; Paypal, Hōʻoia Kūʻai.
ʻŌlelo i ʻōlelo ʻia: English.